Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A meta-analysis

Hepatology Research

Volumn 46, Issue 1, 2016, Pages 58-71

  Wang, Yulan ^a   Deng, Tianxing ^b   Zeng, Li ^a   Chen, Weiqing ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Meta analysis; Radiofrequency ablation; Transcatheter arterial chemoembolization

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; MONOTHERAPY; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 84959340279     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12568     Document Type: Review

References (52)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: Cancer J Clin 2015; (Mar)65: 87-108.
2. Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am 2015; (Jan)24: 1-17.
3. Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; (Mar)53: 1020-2.
4. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; (Apr) 56: 908-43.
5. Bruix J, Castells A, Bosch J, etal. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; (Oct)111: 1018-22.
6. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; (Feb)37: 429-42.
7. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4cm. Gastroenterology 2004; (Dec)127: 1714-23.
8. Li Y, Zheng YB, Zhao W, etal. Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma. Med Oncol 2013; (Dec)30: 730.
9. l Awady MK, Bader El Din NG, Tabll A, etal. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients. World journal of gastroenterology : WJG 2013; (Jan 14)19: 290-8.
10. Rossi S, Ravetta V, Rosa L, etal. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology 2011; (Jan)53: 136-47.
11. Zhao M, Wang JP, Li W, etal. Comparison of safety and efficacy for transcatheter arterial chemoembolization alone and plus radiofrequency ablation in the treatment of single branch portal vein tumor thrombus of hepatocellular carcinoma and their prognosis factors. Zhonghua Yi Xue Za Zhi 2011; (May 10)91: 1167-72.
12. Marelli L, Shusang V, Buscombe JR, etal. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer. J Nucl Med : official publication, Society of Nuclear Medicine 2009; (Jun)50: 871-7.
13. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; (Mar)35: 519-24.
14. Kim JH, Won HJ, Shin YM, etal. Medium-sized (3.1-5.0cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol 2011; (Jun)18: 1624-9.
15. Yan S, Xu D, Sun B. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci 2013; (Jul)58: 2107-13.
16. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 2006; (Mar)16: 661-9.
17. Kim JW, Kim JH, Won HJ, etal. Hepatocellular carcinomas 2-3cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol 2012; (Mar)81: e189-93.
18. Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int : Official Journal of the International Association for the Study of the Liver. 2010; (May)30: 741-9.
19. Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Canc Res Clin Oncol 2013; (Apr)139: 653-9.
20. Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ. Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000; (Sep)7: 593-600.
21. Higgins JP, Altman DG, Gotzsche PC, etal. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
22. Shen SQ, Xiang JJ, Xiong CL, Wu SM, Zhu SS. Intraoperative radiofrequency thermal ablation combined with portal vein infusion chemotherapy and transarterial chemoembolization for unresectable HCC. Hepatogastroenterology 2005; (Sep-Oct)52: 1403-7.
23. Yang P, Liang M, Zhang Y, Shen B. Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC. Adv Ther 2008; (Aug)25: 787-94.
24. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 2009; (Sep)252: 905-13.
25. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010; (Dec 1)116: 5452-60.
26. Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen MS. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 2012; (Feb)262: 689-700.
27. Peng ZW, Zhang YJ, Chen MS, etal. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol : Official Journal of the American Society of Clinical Oncology 2013; (Feb 1)31: 426-32.
28. Bloomston M, Binitie O, Fraiji E, etal. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg 2002; (Sep)68: 827-31.
29. Hsieh CB, Chang HM, Chen TW, etal. Comparison of transcatheter arterial chemoembolization, laparoscopic radiofrequency ablation, and conservative treatment for decompensated cirrhotic patients with hepatocellular carcinoma. World J Gastroenterol: WJG. 2004; (Feb 15)10: 505-8.
30. Chok KS, Ng KK, Poon RT, etal. Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization. Arch Surg 2006; (Dec)141: 1231-6.
31. Murakami T, Ishimaru H, Sakamoto I, etal. Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Intervent Radiol 2007; (Jul-Aug)30: 696-704.
32. Yang MJ, An SY, Moon EJ, etal. Comparison of radiofrequency ablation and transarterial chemoembolization for the treatment of a single hepatocellular carcinoma smaller than 4 cm. Korean J Hepatol 2009; (Dec)15: 474-85.
33. Yang W, Chen MH, Wang MQ, etal. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment. Hepatol Res 2009; (Mar)39: 231-40.
34. Peng ZW, Chen MS, Liang HH, etal. A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol 2010; (Mar)36: 257-63.
35. Hsu CY, Huang YH, Chiou YY, etal. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transplant 2011; (May)17: 556-66.
36. Kim JW, Kim JH, Sung KB, etal. Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2cm or smaller. Am J Gastroenterol 2014; (Aug)109: 1234-40.
37. Liu PH, Lee YH, Hsu CY, etal. Survival advantage of radiofrequency ablation over transarterial chemoembolization for patients with hepatocellular carcinoma and good performance status within the Milan criteria. Ann Surg Oncol 2014; (Nov)21: 3835-43.
38. Yang HJ, Lee JH, Lee DH, etal. Small single-nodule hepatocellular carcinoma: comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting. Radiology 2014; (Jun)271: 909-18.
39. Yin X, Zhang L, Wang YH, etal. Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma. BMC Cancer 2014; 14: 849.
40. Iezzi R, Pompili M, a Torre MF, etal. Radiofrequency ablation plus drug-eluting beads transcatheter arterial chemoembolization for the treatment of single large hepatocellular carcinoma. Dig Liver Dis: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2014; (Dec)13: 242-8.
41. Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol: WJG. 2003; (Sep)9: 1885-91.
42. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 2010; (Mar)52: 380-8.
43. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010; (Aug)7: 448-58.
44. Kainuma O, Asano T, Aoyama H, Shinohara Y. Recurrent hepatocellular carcinoma successfully treated with radiofrequency thermal ablation. J Hepato-biliary-Pancreat Surg 1999; 6: 190-4.
45. Livraghi T, Meloni F, i Stasi M, etal. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008; (Jan)47: 82-9.
46. Yin XY, Xie XY, Lu MD, etal. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer 2009; (May 1)115: 1914-23.
47. Chan AK, Hegarty C, Klass D, etal. The Role of Contrast-Enhanced Ultrasound in Guiding Radiofrequency Ablation of Hepatocellular Carcinoma: A Retrospective Study. Can Assoc Radiol J = Journal l'Association canadienne des radiologistes 2015; (Jan)27: 171-8.
48. Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol: WJG 2013; (Jun 28)19: 3872-82.
49. Tanaka M, Ando E, Simose S, etal. Radiofrequency ablation combined with transarterial chemoembolization for intermediate hepatocellular carcinoma. Hepatol Res: the official journal of the Japan Society of Hepatology 2014; (Feb)44: 194-200.
50. Yamanaka T, Yamakado K, Takaki H, etal. Ablative zone size created by radiofrequency ablation with and without chemoembolization in small hepatocellular carcinomas. Jpn J Radiol 2012; (Aug)30: 553-9.
51. Li ZR, Kang Z, Qian JS, etal. [Radiofrequency ablation with or without transcather arterial chemoembolization for management of hepatocellular carcinoma]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2007; (Nov)27: 1749-51.
52. Gadaleta C, Catino A, Ranieri G, etal. Single-step therapy - feasibility and safety of simultaneous transarterial chemoembolization and radiofrequency ablation for hepatic malignancies. In Vivo 2009; (Sep-Oct)23: 813-20.